Genopis, a U.S offshoot of Helixmith, said that it has entered into a strategic partnership with GenScript for the manufacturing and sale of good manufacturing practice (GMP)-grade plasmid DNA.
Under the accord, GenScript will supply GMP-grade plasmid DNA manufactured by Genopis to global markets, while Genopis will supply its GMP-grade plasmid DNA through GenScript's sales infrastructure.
According to Genopis, GenScript is a biotech company headquartered in New Jersey, U.S., and is listed in the Hong Kong stock market with a market capitalization of about 4.5 trillion won ($3.8 billion), The company major businesses are contract manufacturing organization (CMO) services for research sample, pharmaceutical antibody, gene therapy and cell therapy production.
GenScript has production facilities for gene and cell therapy in China but not in the United States.
"The alliance extends GenScript's service in the field of medicinal plasmid DNA to a global scale," said Brian Min, GenScript CEO responsible for biological drug business unit. "Genopis' clinical and commercial GMP production capabilities are world-class, enabling us to contribute significantly to accelerate the development of innovative medicines."
Genopis CSO Paul Kima also said, "GenScript is a leading biotechnology company specializing in supplying research samples and has an international sales infrastructure for research reagents, as well as pharmaceutical samples, especially for gene and cell therapies."
Through this partnership, the two companies can create a significant synergy effect, Kim added.
<© Korea Biomedical Review, All rights reserved.>